Ber EP4 and epithelial membrane antigen aid distinction of basal cell, squamous cell and basosquamous carcinomas of the skin

Beer, Trevor W.; Shepherd, Phillip; Theaker, J M

doi:10.1046/j.1365-2559.2000.00999.x

Cited by 157 publications

(140 citation statements)

References 22 publications

(52 reference statements)

Supporting

Mentioning

114

Contrasting

Unclassified

Order By: Relevance

“…34 The utility of this antibody in distinguishing basal cell carcinoma and squamous cell carcinoma based upon its consistent expression in the former and absence in the latter is well documented. 35,36 While we also found BerEP4 in all cases of infiltrative basal cell carcinoma in our study, we noted strong BerEP4 expression in 38% our microcystic adnexal carcinoma cases. Similar to our study, Smith et al 23 reported BerEP4 immunoreactivity in glandular areas of their 10 cases of microcystic adnexal carcinoma.…”

Section: Discussionsupporting

confidence: 52%

Microcystic adnexal carcinoma: an immunohistochemical reappraisal

Hoang

Dresser

Kapur³

et al. 2008

Modern Pathology

View full text Add to dashboard Cite

Even though immunohistochemical comparisons of microcystic adnexal carcinoma vs infiltrative basal cell carcinoma and desmoplastic trichoepithelioma exist, they are mostly restricted to the use of a single stain. In addition, a comparison with squamous cell carcinoma has not been reported previously. In this study, we compare the expression of cytokeratin (CK) 15, CK7, CK20, CK903, carcinoembryonic antigen (CEA), CD10, CD15 and BerEP4 in 13 microcystic adnexal carcinoma, eight desmoplastic trichoepithelioma, 10 infiltrative basal cell carcinoma, and eight squamous cell carcinoma of which five exhibited ductal differentiation. We found that the majority of microcystic adnexal carcinoma (92%) and desmoplastic trichoepithelioma (100%) cases expressed CK15 while the infiltrative basal cell carcinoma and squamous cell carcinoma cases were all negative. Forty percent of infiltrative basal cell carcinoma expressed CK7; while only two microcystic adnexal carcinoma cases (15%) and one squamous cell carcinoma with ductal differentiation (12%) expressed CK7 in the remaining three tumor categories. None of the desmoplastic trichoepithelioma expressed CK7. All tumors were strongly positive for CK903. While the neoplastic cells were negative, luminal staining of ductal structures was noted for CK7, CD15 and CEA in some of the microcystic adnexal carcinoma, desmoplastic trichoepithelioma and squamous cell carcinoma with ductal differentiation cases. Sixty percent of infiltrative basal cell carcinoma, 31% of microcystic adnexal carcinoma, and 25% of squamous cell carcinoma express CD10. BerEP4 expression was noted in 38% of microcystic adnexal carcinoma, 57% of desmoplastic trichoepithelioma, 100% of infiltrative basal cell carcinoma, and 38% of squamous cell carcinoma. In conclusion, we found CK15 to be a useful marker in distinguishing microcystic adnexal carcinoma from infiltrative basal cell carcinoma and squamous cell carcinoma with ductal differentiation. Our experience indicates that microcystic adnexal carcinoma and desmoplastic trichoepithelioma have a similar immunohistochemical profile that is, CK15 þ and BerEP4 þ /À; thus, additional studies are needed to separate these two entities.

show abstract

Section: Discussionsupporting

confidence: 52%

Microcystic adnexal carcinoma: an immunohistochemical reappraisal

Hoang

Dresser

Kapur³

et al. 2008

Modern Pathology

View full text Add to dashboard Cite

show abstract

“…It is well known that the expression of EMA is uncommon in BCCs (28,29), which corroborates the results of our present study.…”

Section: -------------------------------------------------Class III ßsupporting

confidence: 93%

Aberrant expression of class III β-tubulin in basal cell carcinoma of the skin

Ishida

Kushima²,

Okabe³

2009

Oncol Rep

View full text Add to dashboard Cite

Abstract. Tubulin is a major component of microtubules. Class III ß-tubulin (ß III) is a neuron-associated ß-tubulin isotype and expressed in the normal central and peripheral nervous systems. According to a previous study, ß III is not expressed in normal skin and squamous cell carcinoma. However, its expression has not been examined in basal cell carcinoma (BCC) of the skin. Expression of ß III was analyzed together with neural cell adhesion molecule (NCAM), chromogranin A, synaptophysin, epithelial membrane antigen (EMA) and cytokeratin (CK) 20 by immunohistochemical methods in 10 non-neoplastic skin tissues and 50 BCCs. In the normal skin, immunoreactivity to ß III was restricted to the nerve bundles in the dermis and subcutis, no positivity was shown in epithelial cells of the epidermis and skin appendages. ß III and NCAM were expressed in 50 and 68% of BCCs, respectively, predominantly periphery of tumor nests, although the distribution of both markers was not always identical. Chromogranin A, synaptophysin and CK 20 were not expressed in any of BCCs. EMA was focally expressed in only 8% of BCCs. ß III is a potential candidate for inclusion to the panel of immunohistochemical markers to distinguish small BCCs from non-neoplastic hair buds, because non-neoplastic hair follicles are not positive for ß III.

show abstract

“…Ber-EP4 has been proven to be negative in peripheral ameloblastomas [11,12]. Additionally, epithelial membrane antigen (EMA) a mucinlike glycoprotein often used as a pan-epithelial marker has been utilized to differentiate BCC from SCC, especially since some variants of SCC such as basaloid SCC may resemble BCC [13,14].…”

Section: Discussionmentioning

confidence: 99%